182 related articles for article (PubMed ID: 30657422)
1. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
Cazzola M; Page C; Calzetta L; Matera MG
Pharm Pat Anal; 2018 Nov; 7(6):249-257. PubMed ID: 30657422
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
3. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Investig Drugs; 2019 Oct; 28(10):827-833. PubMed ID: 31474120
[No Abstract] [Full Text] [Related]
4. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
Singh D; Martinez FJ; Watz H; Bengtsson T; Maurer BT
Respir Res; 2020 Feb; 21(1):47. PubMed ID: 32041601
[TBL] [Abstract][Full Text] [Related]
5. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials.
Cazzola M; Page C; Calzetta L; Singh D; Rogliani P; Matera MG
Immunotherapy; 2023 Dec; 15(18):1511-1519. PubMed ID: 37779474
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.
Bjermer L; Abbott-Banner K; Newman K
Pulm Pharmacol Ther; 2019 Oct; 58():101814. PubMed ID: 31202957
[TBL] [Abstract][Full Text] [Related]
7. Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective.
Gan Q; Wu Y; Su X; Wang J; Zhang H; Zhang N; Wu K
Am J Respir Crit Care Med; 2024 Jan; 209(2):223-224. PubMed ID: 37939381
[No Abstract] [Full Text] [Related]
8. Dual PDE 3/4 inhibition: a novel approach to airway disease?
Wedzicha JA
Lancet Respir Med; 2013 Nov; 1(9):669-70. PubMed ID: 24429260
[No Abstract] [Full Text] [Related]
9. Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Donohue JF; Rheault T; MacDonald-Berko M; Bengtsson T; Rickard K
Int J Chron Obstruct Pulmon Dis; 2023; 18():1611-1622. PubMed ID: 37533771
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.
Calzetta L; Cazzola M; Page CP; Rogliani P; Facciolo F; Matera MG
Pulm Pharmacol Ther; 2015 Jun; 32():15-23. PubMed ID: 25899618
[TBL] [Abstract][Full Text] [Related]
11. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
Singh D; Lea S; Mathioudakis AG
Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
[TBL] [Abstract][Full Text] [Related]
12. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia.
Turner MJ; Matthes E; Billet A; Ferguson AJ; Thomas DY; Randell SH; Ostrowski LE; Abbott-Banner K; Hanrahan JW
Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(1):L59-70. PubMed ID: 26545902
[TBL] [Abstract][Full Text] [Related]
13. The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4.
Turner MJ; Dauletbaev N; Lands LC; Hanrahan JW
J Pharmacol Exp Ther; 2020 Dec; 375(3):414-429. PubMed ID: 33012706
[TBL] [Abstract][Full Text] [Related]
14. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
Martin C; Burgel PR; Roche N
Int J Chron Obstruct Pulmon Dis; 2021; 16():2363-2373. PubMed ID: 34429594
[TBL] [Abstract][Full Text] [Related]
15. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
16. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone.
Calzetta L; Page CP; Spina D; Cazzola M; Rogliani P; Facciolo F; Matera MG
J Pharmacol Exp Ther; 2013 Sep; 346(3):414-23. PubMed ID: 23766543
[TBL] [Abstract][Full Text] [Related]
17. PDE inhibitors currently in early clinical trials for the treatment of asthma.
Matera MG; Page C; Cazzola M
Expert Opin Investig Drugs; 2014 Sep; 23(9):1267-75. PubMed ID: 24865624
[TBL] [Abstract][Full Text] [Related]
18. The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.
Turner MJ; Luo Y; Thomas DY; Hanrahan JW
Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L908-L920. PubMed ID: 32159371
[TBL] [Abstract][Full Text] [Related]
19. Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.
Watz H; Rickard K; Rheault T; Bengtsson T; Singh D
Int J Chron Obstruct Pulmon Dis; 2020; 15():2199-2206. PubMed ID: 32982212
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
